<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363474">
  <stage>Registered</stage>
  <submitdate>11/01/2013</submitdate>
  <approvaldate>14/01/2013</approvaldate>
  <actrnumber>ACTRN12613000039785</actrnumber>
  <trial_identification>
    <studytitle>A randomised trial of zoledronic acid for osteoarthritis of the knee</studytitle>
    <scientifictitle>Patients with knee pain, knee osteoarthritis and bone marrow lesions, randomised to zoledronic acid or placebo, assessed by knee cartilage volume loss over 24 months, knee pain at 3, 6, 12, 18, and 24 months, and bone marrow lesion size over 6 and 24 months</scientifictitle>
    <utrn />
    <trialacronym>ZAP2</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Knee pain
</healthcondition>
    <healthcondition>Knee osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>5mg by short IV infusion annually, zoledronic acid, annually for 2 years </interventions>
    <comparator>5mg of normal saline, annually for 2 years</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Magnetic resonance imaging assessment of cartilage volume loss</outcome>
      <timepoint>24 months following commencement of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Knee pain as measured by visual analogue score and WOMAC</outcome>
      <timepoint>3, 6, 12, 18, and 24 months following the commencement of treatment </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Magnetic resonance imaging assessment of bone marrow lesions</outcome>
      <timepoint>6 and 24 months following commencement of treatment </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1)	Aged over 50 years old

2)	Men and women with significant knee pain on most days (defined as a Visual Analog Score &gt; 40 mm)

3)	Bone marrow lesion present on MRI 

4)	Meet American College of Rheumatology (ACR) clinical criteria for knee osteoarthritis
</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1)	Prior use of bisphosphonates, except according to the washout schedule:
2 years (if use &gt;48 weeks)
1 year (if used &gt;8 weeks but &lt;48 weeks)
6 months (if used &gt;2 weeks but &lt;8 weeks)
2 months (if used &lt;2 weeks)
Any IV bisphosphonate within the prior 2 years

2)	History of non-traumatic iritis or uveitis

3)	Abnormal blood tests [serum calcium &gt;2.75 mmol/L (11.0 mg/dL) or &lt;2.00 mmol/L (8.0 mg/dL) or creatinine clearance &lt; 35 ml/min]

4)	Serum 25-hydroxyvitamin D concentrations &lt;15 ng/L

5)	Use of any investigational drug(s) and/or devices within 30 days prior to randomisation

6)	Prior diagnosis of cancer (metastatic cancer or cancer diagnosed &lt; 2 years ago where treatment is still ongoing)

7)	A dental exam with appropriate preventative dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, corticosteroids, poor hygiene)

8)	Severe knee osteoarthritis (joint space narrowing (JSN)) on X-ray of Grade 3 using the Osteoarthritis Research Society International (OARSI) atlas).
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>20/06/2013</anticipatedstartdate>
    <actualstartdate>23/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>18/09/2015</actualenddate>
    <samplesize>264</samplesize>
    <actualsamplesize>271</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>18/09/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,TAS,VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Menzies Research Institute Tasmania, University of Tasmania</primarysponsorname>
    <primarysponsoraddress>Medical Science 1
17 Liverpool St
Hobart, TAS
7000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Alfred Hospital, Monash University</sponsorname>
      <sponsoraddress>Department of Epidemiology &amp; Preventive Medicine
Level 3, Burnet Building, Commerical Road
Melbourne, VIC
3004</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal North Shore Hospital, University of Sydney</sponsorname>
      <sponsoraddress>E25 - Royal North Shore Hospital
The University of Sydney
Sydney, NSW
2006</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>The Queen Elizabeth Hospital</sponsorname>
      <sponsoraddress>Rheumatology Unit, The Queen Elizabeth Hospital
28 Woodville Road
Woodville, SA
5011
</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to compare, using a randomised, placebo-controlled double-blind design over two years, the effect of an annual infusion of zoledronic acid to placebo on knee structural change assessed on MRI and knee pain in patients with knee osteoarthritis, significant knee pain and an MRI detected knee bone marrow lesion. We will recruit 264 subjects in Hobart, Melbourne, Sydney, and Adelaide. Eligible subjects will receive an annual identical intravenous infusion of zoledronic acid (5mg in normal saline) or placebo (normal saline), over two years. Outcome measures include cartilage loss over 24 months, knee pain at 3, 6, 12, 18, and 24 months, and bone marrow lesion size over 6 and 24 months.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tasmania Health &amp; Medical Human Research Ethics Committee (EC00337)</ethicname>
      <ethicaddress>Office of Research Services
University of Tasmania
Private Bag 01
Hobart TAS 7001
</ethicaddress>
      <ethicapprovaldate>9/01/2013</ethicapprovaldate>
      <hrec>H0012941</hrec>
      <ethicsubmitdate>3/12/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee (EC00315)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Northern Sydney Coast Human Research Ethics Committee (EC00112)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Human Research Ethics Committtee (TQEH/LMH/MH) (EC00190)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Graeme Jones</name>
      <address>Medical Science 2
17 Liverpool St
Hobart, TAS
7000</address>
      <phone>+61 03 6226 7705</phone>
      <fax>+61 03 6226 7704</fax>
      <email>g.jones@utas.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Graeme Jones</name>
      <address>Medical Science 2
17 Liverpool St
Hobart, TAS
7000</address>
      <phone>+61 03 6226 7705</phone>
      <fax>+61 03 6226 7704</fax>
      <email>g.jones@utas.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Graeme Jones</name>
      <address>Medical Science 2
17 Liverpool St
Hobart, TAS
7000</address>
      <phone>+61 03 6226 7705</phone>
      <fax>+61 03 6226 7704</fax>
      <email>g.jones@utas.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Graeme Jones</name>
      <address>Medical Science 2
17 Liverpool St
Hobart, TAS
7000</address>
      <phone>+61 03 6226 7705</phone>
      <fax>+61 03 6226 7704</fax>
      <email>g.jones@utas.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>